Publications by authors named "W Graybill"
Article Synopsis
- The study analyzes the cost differences in managing hematologic adverse events (AEs) for the individualized starting dose (ISD) versus the fixed starting dose (FSD) of niraparib from a US payer perspective.
- Data from a phase III trial provided AE occurrence rates, and costs were calculated based on 2020 adjustments from a healthcare database.
- Results showed that managing AEs was significantly cheaper with ISD ($6744.93) compared to FSD ($12,987.71), suggesting ISD not only cuts costs but also improves patient safety.
Article Synopsis
- This study examines the combined effects of the PARP inhibitor niraparib and statins on progression-free survival in ovarian cancer patients.
- The analysis of clinical trials showed that patients taking niraparib experienced better progression-free survival compared to those on placebo (13.8 months vs 8.2 months).
- Notably, patients using both niraparib and statins had significantly better outcomes than those on placebo with statins, highlighting potential benefits of combining these treatments and the need for more research in this area.
Background: The phase III PRIMA/ENGOT-OV26/GOG-3012 trial met its primary endpoint. Niraparib first-line maintenance significantly prolonged progression-free survival (PFS) among patients with newly diagnosed advanced ovarian cancer that responded to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. Final overall survival (OS) results are reported.
View Article and Find Full Text PDFArticle Synopsis
- The study analyzed how advanced ovarian cancer patients respond to niraparib maintenance therapy and patterns of disease recurrence.
- Of 314 patients, 190 developed new lesions, primarily in the peritoneum, lymph nodes, and liver, often seeing 1-3 new lesions upon progression.
- Findings suggest that while many patients develop oligometastatic disease at recurrence, further research is needed to assess if local therapies could enhance outcomes when combined with targeted maintenance therapy.
Purpose: Niraparib is a poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor approved for the maintenance treatment of advanced ovarian cancer (OC). Niraparib was originally approved in recurrent OC at a fixed starting dose (FSD) of 300 mg once daily (QD). This analysis characterized the population pharmacokinetics (PK) of niraparib and evaluated the relationships between exposure, efficacy, and safety to support clinical use of an individualized dosing strategy, in which the starting dose of niraparib was adjusted based on patient characteristics to improve the benefit-risk profile.
View Article and Find Full Text PDF